The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging participation in the WHO Programme for International Drug... Monitoring. This text was developed in consultation with the WHO Collaborating Centre for International Drug Monitoring and the national pharmacovigilance centres participating in the WHO Programme for International Drug Monitoring.
more
Recommendations for health care professionals – the experience from Latvia
Conflict, climate crisis and COVID-19 pose great threats to the health of women and children.
The guidelines address timing, number and place of postnatal contacts, and content of postnatal care for all mothers and babies during the six weeks after birth. The primary audience for these guidelines is health professionals who are responsible for providing postnatal care to women and newborns, ...primarily in areas where resources are limited. The guidelines are also expected to be used by policy-makers and managers of maternal and child health programmes, health facilities, and teaching institutions to set up and maintain maternity and newborn care services.
more
COVID-19: Tools for Social and Behavior Change
Page en français Social and behavior change (SBC) professionals are well positioned to address COVID-19 interventions. We offer two Trending Topics – This one, with Tools for SBC Professionals and another with Materials and Resources for the Publi...c. Both will be updated often We welcome contributions to this collection by uploading your materials here or
more
Q3: What approaches are available to enable non-specialized health care providers to identify children with intellectual disabilities, including intellectual disabilities due to specific causes?
Why a 4°C warmer world must be avoided
WHO clinical and policy guidelines